/ Print /

Health/Disease Strategy

Six things to know about CMS' new bundled payment modelCMS unveiled a voluntary episode bundled payment model, Bundled Payments for Care Improvement Advanced (BPCI Advanced). Here’s six things experts want you to know
Four COPD treatment changes to watchPending and recently approved treatment options for patients with chronic obstructive pulmonary disease range from biologics to a triple-drug inhaler.
Three ways healthcare executives can uncover consumers at risk for fluWith influenza activity increasing sharply, here’s how healthcare executives can determine which health plan members are at risk for the flu.
CAR T-cell therapies in treating lymphoma: Pros and consCatherine Bollard, MD, discusses the success rate of CAR T-cell treatments, remaining obstacles, and top payer considerations.
Autoimmune drug pipeline highlightsMore targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
Four risks healthcare executives should monitor in 2018With the right preventions in place, hospitals and healthcare executives will be well positioned to respond to these four risks in 2018.
Three ways to make healthcare consumers happierA new survey has eye-opening findings about the status quo one-size-fits-all health plan.
New high blood pressure guideline healthcare cost impactFifty percent of Americans have high blood pressure, per new guidelines. Here’s how those guidelines could affect medication utilization and healthcare spending.
Five key elements of successful local initiatives to combat the opioid crisisSuccessful community initiatives are creating systems of care that bridge multiple programs to provide coordinated services to individuals with substance use disorders. Here are five.
Three things health execs need to know about CAR T-cell therapyHere’s your quick guide to understanding how CAR T-cell therapy could affect patients and payers.